UNITED THERAPEUTICS CorpUTHREarnings & Financial Report
United Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; ...
UTHR Q4 FY2025 Key Financial Metrics
Revenue
$790.2M
Gross Profit
$686.8M
Operating Profit
$356.7M
Net Profit
$364.3M
Gross Margin
86.9%
Operating Margin
45.1%
Net Margin
46.1%
YoY Growth
7.4%
EPS
$7.66
UNITED THERAPEUTICS Corp Q4 FY2025 Financial Summary
UNITED THERAPEUTICS Corp reported revenue of $790.2M (up 7.4% YoY) for Q4 FY2025, with a net profit of $364.3M (up 20.9% YoY) (46.1% margin). Cost of goods sold was $103.4M, operating expenses totaled $330.1M.
Key Financial Metrics
| Total Revenue | $790.2M |
|---|---|
| Net Profit | $364.3M |
| Gross Margin | 86.9% |
| Operating Margin | 45.1% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
UNITED THERAPEUTICS Corp Q4 FY2025 revenue of $790.2M breaks down across 7 segments, led by Tyvaso DPI at $338.6M (42.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Tyvaso DPI | $338.6M | 42.8% |
| Remodulin | $128.0M | 16.2% |
| Nebulized Tyvaso | $125.7M | 15.9% |
| Orenitram | $121.2M | 15.3% |
| Unituxin | $62.3M | 7.9% |
| Adcirca | $7.8M | 1.0% |
| Other | $6.6M | 0.8% |
UNITED THERAPEUTICS Corp Revenue by Segment — Quarterly Trend
UNITED THERAPEUTICS Corp revenue by segment across the last 4 reported quarters, showing how each business line (such as Tyvaso DPI and Remodulin) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Tyvaso DPI | $338.6M | $336.2M | $315.2M | $302.5M |
| Remodulin | $128.0M | $125.9M | $134.7M | $138.2M |
| Nebulized Tyvaso | $125.7M | $141.8M | $154.4M | $163.8M |
| Orenitram | $121.2M | $131.1M | $123.9M | $120.7M |
| Unituxin | $62.3M | $47.9M | $58.4M | $58.2M |
UNITED THERAPEUTICS Corp Annual Revenue by Year
UNITED THERAPEUTICS Corp annual revenue history includes year-by-year totals (for example, 2025 revenue was $3.2B).
UNITED THERAPEUTICS Corp Quarterly Revenue & Net Profit History
UNITED THERAPEUTICS Corp results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $790.2M | +7.4% | $364.3M | 46.1% |
| Q3 FY2025 | $799.5M | +6.8% | $338.7M | 42.4% |
| Q2 FY2025 | $798.6M | +11.7% | $309.5M | 38.8% |
| Q1 FY2025 | $794.4M | +17.2% | $322.2M | 40.6% |
| Q4 FY2024 | $735.9M | +19.7% | $301.3M | 40.9% |
| Q3 FY2024 | $748.9M | +22.9% | $309.1M | 41.3% |
| Q2 FY2024 | $714.9M | +19.8% | $278.1M | 38.9% |
| Q1 FY2024 | $677.7M | +33.7% | $306.6M | 45.2% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $677.7M | $714.9M | $748.9M | $735.9M | $794.4M | $798.6M | $799.5M | $790.2M |
| YoY Growth | 33.7% | 19.8% | 22.9% | 19.7% | 17.2% | 11.7% | 6.8% | 7.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $6.50B | $6.72B | $7.12B | $7.36B | $7.74B | $7.91B | $7.35B | $7.88B |
| Liabilities | $1.16B | $1.03B | $1.02B | $920.0M | $936.7M | $734.4M | $760.9M | $783.8M |
| Equity | $5.34B | $5.70B | $6.10B | $6.44B | $6.81B | $7.17B | $6.59B | $7.10B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $376.5M | $232.2M | $377.2M | $341.2M | $461.2M | $191.7M | $562.1M | $346.2M |